English | 简体中文 | 繁體中文 | 한국어 | 日本語
Wednesday, 3 April 2024, 20:00 HKT/SGT

Source: Clairvoyant Therapeutics
Psilocybin Clinical Trial Sponsored by Clairvoyant Therapeutics Reaches 90% Randomization
Clairvoyant on target for potential commercialization of psilocybin treatment in 2025

Vancouver, BC, Apr 3, 2024 - (ACN Newswire) - Clairvoyant Therapeutics Inc. (www.clairvoyantrx.com), the private clinical-stage pharmaceutical company developing psilocybin treatment for alcohol use disorder (AUD), today announced that it is on target to potentially become the first in the world to commercialize clinically validated psilocybin treatment. Clairvoyant believes it may achieve this milestone in H2 2025.

Clairvoyant's randomized controlled trial, CLA-PSY-201, has dosed more than 90 per cent of the expected 128 subjects for its 24-week Phase 2b clinical trial of synthetic psilocybin treatment for AUD (two dosing sessions of a 25 mg oral capsule over 8 weeks) at 12 active clinical sites in Canada and Europe. A top line read out from the clinical trial is expected in Q3 2024 and a Series A financing round is currently underway.

"We are quickly approaching a critical and exciting moment for psilocybin and its potential use as a recognized treatment," said Damian Kettlewell, CEO, Clairvoyant. "We have the compelling efficacy and safety data on psilocybin treatment for AUD from a phase 2a study previously published in JAMA Psychiatry[i] in 2022 and earlier data published in 2015. Assuming our trial has similar results, we believe there is a regulatory pathway to conditional market authorization in Canada in 2025 and in the EU in 2026."

Conditional marketing authorization of psilocybin would be based on recognition of AUD as a serious, life-threatening or severely debilitating disease for which psilocybin demonstrates a significant increase in efficacy in relation to existing AUD drugs. Conditional authorization of a new medicine, known as NOC/c in Canada and CMA in Europe, allows the marketing of a new drug with the condition that the sponsor undertake additional studies to verify the clinical benefit. Under NOC/c and CMA, companies are required to conduct confirmatory studies to validate the initial efficacy evidence. Clairvoyant intends to launch a pivotal confirmatory trial in H2 2025, with a read out in 2027, to support full approval of psilocybin treatment in Canada, the EU and UK.

About Patient Safety

Clairvoyant is committed to ensuring the safety and well-being of participants. Participants are supported by two therapists in preparation for, and during, the psychedelic experience induced by psilocybin. Clairvoyant has trained over 50 therapists in its 35-hour training program. Therapists are monitored for adherence to the trial protocol and ethics under Clairvoyant's industry leading therapist adherence monitoring program. No ethical concerns have been identified to date.

About Alcohol Use Disorder

Alcohol is the leading risk factor for overall burden of disease among men and a significant risk factor among women.[ii] A regional study recently reported that fewer than 5 per cent of patients diagnosed with moderate to severe alcohol use disorder receive recommended medications.[iii]

About Clairvoyant Therapeutics

Clairvoyant Therapeutics is a Canadian biotechnology company trailblazing a path to global mental health through psilocybin treatment. Clairvoyant's speed-to-market clinical strategy is designed to enable psilocybin treatment in Canada, EU & the UK for patients living with Alcohol Use Disorder (AUD) beginning in 2025.

The company's exceptional team, with deep clinical development experience, has made Clairvoyant the most advanced company developing psilocybin for the treatment of AUD. Clairvoyant is a member of Life Sciences BC.

Additional information about Clairvoyant's clinical trial may be found at ClinicalTrials.gov

For more information:
Damian Kettlewell

[i] Bogenschutz, MP et al. (2022) JAMA Psychiatry. 2022;79(10):953-962. doi:10.1001/jamapsychiatry.2022.2096

[ii] World Health Organization. Global Status Report on Alcohol and Health 2014 Accessed March 2024 at WHO Global Status Report on Alcohol and Health 2014

[iii] Maria Eugenia SociasFrank Xavier ScheuermeyerZizhan CuiWing Yin MokAlexis CrabtreeNadia FairbairnSeonaid NolanAmanda SlaunwhiteLianping Ti. (2023) Addiction. 2023; Volume118, Issue11: 2128-2138. doi.org/10.1111/add.16273

SOURCE: Clairvoyant Therapeutics

Topic: Company Update

Related Documents:
clairvoyant w&b horizontal (1)

Topic: Press release summary
Source: Clairvoyant Therapeutics

Sectors: Healthcare & Pharm
From the Asia Corporate News Network

Copyright © 2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.


Latest Press Releases
Vietnam: International Dairy Product launches nutritious KUN milk with jelly pieces in SIG XSlimBloc carton packs  
May 20, 2024 19:30 HKT/SGT
InsureTech Connect Asia: Asia's Largest Insurance Ecosystem Conference  
May 20, 2024 18:08 HKT/SGT
BEAST (Bengkel Animasi Digital Arts & Creative Festival) 2024 goes back to Bandung  
May 20, 2024 18:00 HKT/SGT
Paw Pro GmbH Announces $1.5M Partnership with Health Reasoning to Launch Innovative Web3 Platform  
May 20, 2024 17:03 HKT/SGT
Response to Africa Intelligence Article  
May 20, 2024 17:00 HKT/SGT
Shaping a Green Future for Textile Industry- Aimer 2024 New Presentation of Seaweed Fiber Pajamas  
May 20, 2024 17:00 HKT/SGT
Raytech Holding: Making Nasdaq Debut as It Pioneers Personal Care Electrical Appliances in a Booming Market  
May 20, 2024 16:00 HKT/SGT
The cybersecurity capital of Philippines, PhilSec now an essential choice for critical infrastructure   
May 20, 2024 15:43 HKT/SGT
MHI Receives Order for Additional 12 Units of the Outer Vertical Target for the Divertor Used in the ITER in Southern France  
Monday, May 20, 2024 10:36:00 AM
REDEX to be an exclusive partner to TNBX in Malaysia to support the Malaysia Green Attribute Trading System (mGATS) platform  
May 20, 2024 10:00 HKT/SGT
More Press release >>
More events >>
Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575